Effects of Vibrating Mesh Nebulisation in Patients with COPD During Non-invasive Ventilation (VMN-NIV)

Launched by GUY'S AND ST THOMAS' NHS FOUNDATION TRUST · Mar 17, 2025

Keywords

ClinConnect Summary

This clinical trial, called "Effects of Vibrating Mesh Nebulisation in Patients with COPD During Non-invasive Ventilation," is exploring how two different types of nebulizers—vibrating mesh and jet nebulizers—affect patients with Chronic Obstructive Pulmonary Disease (COPD) who use non-invasive ventilation (a method to help with breathing without needing a breathing tube). The study aims to understand how these nebulizers impact the muscles used for breathing, the way air flows in and out of the lungs, heart rate, and the feeling of breathlessness.

To participate in this trial, you need to be between 18 and 80 years old and have COPD that requires you to use home non-invasive ventilation for at least four hours a day. You should also be stable, meaning you haven't had a sudden worsening of your condition for at least two weeks. If you qualify, you can expect to try out one of the nebulizers during the study while sharing how you feel about your breathing and any symptoms you experience. Please note that certain serious health issues or cognitive challenges could prevent some people from joining the trial. This study is not yet recruiting participants but aims to help improve the care for patients with COPD.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with COPD receiving home non-invasive ventilation for chronic respiratory failure under the Lane Fox Respiratory Service at Guy's and St Thomas' NHS Foundation Trust
• • Tolerating home non-invasive ventilation for at least 4 hours/24 hours
• • Aged 18-80 years old
• • Able to communicate symptom burden to the research team
• • Able to give informed consent for participation in the study
• • Clinical stability, with no acute exacerbations of COPD for 2 weeks prior to enrolment
• Exclusion Criteria:
• * Severe, non-respiratory organ dysfunction including, but not limited to:
• • Congestive cardiac failure
• • Significant cardiovascular disease
• • End-stage malignancy
• • End-stage renal failure
• * Acute pulmonary pathology requiring emergency treatment including, but not limited to:
• • Pneumonia
• • Pneumothorax
• • Pulmonary embolism
• • Severe cognitive impairment
• • Psychosocial factors that would preclude completion of the study protocol